11 Oct
2022
16:30 E.S.T.

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Read more

05 Oct
2022
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Read more

28 Sep
2022
16:25 E.S.T.

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

Read more

01 Sep
2022
16:30 E.S.T.

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

Read more

04 Aug
2022
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Read more

01 Aug
2022
16:30 E.S.T.

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

Read more

28 Jul
2022
16:30 E.S.T.

Cellectis to Report Second Quarter 2022 Financial Results

Read more

30 Jun
2022
05:00 E.S.T.

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Read more

28 Jun
2022
16:30 E.S.T.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Read more

28 Jun
2022
16:05 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Read more